Practical Neurology® magazine covers neurologic advances in epilepsy, stroke, dementia, movement disorders, headache, ALS, breaking neurology news & more.
- Tweets 5,131
- Following 232
- Followers 18,840
- Likes 177
Higher baseline #CSF kappa free light chain levels and kappa index were independently associated with a lower likelihood of maintaining NEDA-3 at 5 years in patients with #multiple_sclerosis.
Data presented at #MSToronto2026.
ow.ly/6eFk5102Cg8
@ACTRIMS @ECTRIMS @mssociety
3
14
582
Early phase 1 data presented at #MSToronto2026 suggest that the investigational CAR T-cell therapy #azer-cel was generally well tolerated in people with refractory progressive #MultipleSclerosis.
Disability scores and imaging/biomarker measures were stable or improved in most evaluable participants.
ow.ly/4B5g5102C5j
@TGTherapeutics @ACTRIMS @ECTRIMS @mssociety
1
3
621
Freezing of gait can be difficult to capture—and even harder to treat.
John B. Sanderson, MD, reviews wearable sensing, adaptive cueing, and #neuromodulation technologies being studied in #ParkinsonDisease.
ow.ly/gsZN5101Un9
@movedisorder @UW #MedTech
1
6
23
1,578
In relapsing #MultipleSclerosis, treatment with the investigational oral BTK inhibitor #remibrutinib was associated with significant reductions in relapse rates and MRI lesion activity.
Findings from the phase 3 #REMODEL trials were presented at #MSToronto2026 and published in @TheLancet.
ow.ly/831T5101UcH
@ACTRIMS @ECTRIMS @mssociety @Novartis
3
9
690
Higher baseline CSF sTREM2 levels were linked to increased risk of PIRA over 5 years in early RRMS but showed limited standalone predictive value, according to findings presented at #MSToronto2026.
ow.ly/uW6N5101szn
@ECTRIMS @ACTRIMS #MultipleSclerosis #MSResearch #Biomarkers
3
8
900
Digital neurologic assessments using #Neuraccure identified subtle impairments linked to disability progression in patients with RRMS despite no recent relapse or MRI activity, according to data presented at #MSToronto2026.
ow.ly/LNmf5101qwe
@ECTRIMS @ACTRIMS #MultipleSclerosis #SPMS #DigitalHealth
2
7
640
About 1 in 12 patients with PPMS diagnosed under the 2017 McDonald criteria did not meet the 2024 criteria using original diagnostic data, raising concerns about additional testing and delays.
ow.ly/4PNT51017ct
#MSToronto2026 @ECTRIMS @ACTRIMS #MultipleSclerosis #PPMS #MSResearch #2024McDonaldCriteria
1
1
4
687
Reduced MS-related fatigue following cognitive behavioral therapy (CBT) was associated with better work functioning for up to 1 year, according to a secondary trial analysis presented at #MSToronto2026.
ow.ly/Ua5B5100zBp
@ECTRIMS @ACTRIMS #MultipleSclerosis #MSResearch #CBT
9
649
Menopause was associated with greater walking disability and physical fatigue in women with MS, but not increased brain or spinal cord atrophy, according to POINT-MS data presented at #MSToronto2026.
ow.ly/a3Mj5100yJH
@ECTRIMS @ACTRIMS #MultipleSclerosis #WomensHealth #MSResearch
2
4
677
MRI analysis identified 4 distinct MS subtypes, with cortex-led and deep gray matter/cerebellar-led patterns linked to greater disability and shorter PIRA-free survival, according to data presented at #MSToronto2026.
ow.ly/78fm5100ubt
@ECTRIMS @ACTRIMS #MultipleSclerosis #MSResearch #Neuroimaging
1
3
6
760
CD19 CAR T-cell therapy zola-cel showed early disease control in refractory relapsing and progressive MS, with manageable safety in the phase 1 Breakfree-2 study presented at #MSToronto2026.
ow.ly/j6Gm5100tsM
@ECTRIMS @ACTRIMS #MultipleSclerosis #CARTCellTherapy #MSResearch
1
16
1,002
Rituximab was noninferior to ocrelizumab for MRI lesion control in newly diagnosed relapsing MS, but infections were more frequent with rituximab, according to phase 3 OVERLORD-MS data at #MSToronto2026.
ow.ly/Aphn5100tbp
@ECTRIMS @ACTRIMS #MultipleSclerosis #MSResearch
4
17
1,154
Satralizumab was associated with fewer MOGAD relapses (13.2% vs 37.5%) and greater postattack recovery in exploratory phase 3 METEOROID data presented at #MSToronto2026.
ow.ly/zPHZ5100t78
@Roche @ECTRIMS @ACTRIMS #MOGAD #Neuroimmunology #Neurology
2
11
762
Fenebrutinib more than halved relapse rates vs teriflunomide and improved MRI and NfL outcomes in a pooled phase 3 FENhance analysis of 1,497 patients with relapsing MS at #MSToronto2026.
ow.ly/qOeK5100hJk
@Roche @ECTRIMS @ACTRIMS #MultipleSclerosis #MSResearch
1
7
676
Early high-efficacy DMT was associated with 36% fewer relapses in MS but did not significantly delay PIRA vs treatment escalation, according to a Danish study presented at #MSToronto2026.
ow.ly/uOi75100agV
@ECTRIMS @ACTRIMS #MultipleSclerosis #MSResearch #Neurology
5
17
935
MRI activity without relapses was linked to higher risk of PIRA, SPMS, and disability worsening in MS, according to an MSBase study of 19,262 patients presented at #MSToronto2026.
ow.ly/eoGK5100b5P
@ECTRIMS @ACTRIMS #MultipleSclerosis #MSResearch #Neurology
4
550
What increases the risk of late-onset epilepsy?
A new JAMA Neurology analysis of 42,257 US adults links #stroke, #diabetes, smoking, kidney disease, and #hypertension to higher epilepsy incidence after age 65. @AmEpilepsySoc @JAMANetwork
ow.ly/LEwv50ZZ8L3
#Epilepsy #Neurology
3
8
756
Clene has submitted an @FDA application seeking accelerated approval of CNM-Au8 as treatment for those diagnosed with amyotrophic lateral sclerosis (ALS), citing neurofilament light chain biomarker data.
ow.ly/GMzp50ZZ8y6
@alsassociation
#ALS #CNMAu8 #Neurology #Neuromuscular
1
6
698
Adults taking enzyme-inducing antiseizure medications had 51% higher adjusted odds of osteoporosis or osteopenia, yet only 20.7% had documented vitamin D supplementation, according to research presented at @ANAneurology #ANA2026.
ow.ly/HyP050ZZ8tM
#Epilepsy #BoneHealth #Neurology
4
14
1,761
Investigational adrabetadex was linked to preservation of neurological function for over 10 years in 2 sisters with infantile-onset Niemann-Pick disease type C. New data presented at @ChildNeuroSoc #CNSAM.
ow.ly/4zLk50ZZ8oZ
#NiemannPick #RareDisease #PediatricNeurology
3
581